Galectin Therapeutics Inc.
GALT
$2.41
$0.010.42%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 28.91% | -9.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 21.16% | -19.84% | |||
| Operating Income | -21.16% | 19.84% | |||
| Income Before Tax | 8.25% | 32.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 8.25% | 32.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 8.25% | 32.80% | |||
| EBIT | -21.16% | 19.84% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 10.36% | 32.94% | |||
| Normalized Basic EPS | 9.79% | 33.38% | |||
| EPS Diluted | 10.36% | 32.94% | |||
| Normalized Diluted EPS | 9.79% | 33.38% | |||
| Average Basic Shares Outstanding | 1.60% | 0.84% | |||
| Average Diluted Shares Outstanding | 1.60% | 0.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||